Search results for "phases"

showing 10 items of 282 documents

Multipactor RF Breakdown in Coaxial Transmission Lines With Digitally Modulated Signals

2016

The aim of this paper is the study of the RF multipactor breakdown in coaxial transmission lines excited by a single carrier with a digitally modulated signal. Employing an in-house developed code, numerical simulations are performed to determine the RF multipactor voltage threshold for several digitally modulated signals under different modulations schemes: quadrature phase-shift keying, 16-quadrature amplitude modulation, 16-amplitude and phase-shift keying, and 32-amplitude and phase-shift keying. Moreover, a coarse method based on the envelope integration to determine the RF multipactor voltage threshold when involving arbitrary digital modulations is also presented. These results are a…

Multipactor effectEngineeringAcoustics02 engineering and technology01 natural sciences010305 fluids & plasmasHarmonic analysisAmplitude modulationDigital modulationTEORIA DE LA SEÑAL Y COMUNICACIONES0103 physical sciences0202 electrical engineering electronic engineering information engineeringElectronic engineeringElectrical and Electronic EngineeringQuadrature amplitude modulation (QAM)Coaxial waveguidesbusiness.industry20-gap-crossing ruleRoot-raised-cosine filterRF breakdown020206 networking & telecommunicationsKeyingElectronic Optical and Magnetic MaterialsElectric power transmissionAmplitude and phaseshift keying (APSK)Multipactor effectRadio frequencybusinessQuadrature phase-shift keying (QPSK)Phase-shift keyingVoltageIEEE Transactions on Electron Devices
researchProduct

Instability of Equilibrium States for Coupled Heat Reservoirs at Different Temperatures

2007

Abstract We consider quantum systems consisting of a “small” system coupled to two reservoirs (called open systems). We show that such systems have no equilibrium states normal with respect to any state of the decoupled system in which the reservoirs are at different temperatures, provided that either the temperatures or the temperature difference divided by the product of the temperatures are not too small. Our proof involves an elaborate spectral analysis of a general class of generators of the dynamics of open quantum systems, including quantum Liouville operators (“positive temperature Hamiltonians”) which generate the dynamics of the systems under consideration.

Non-equilibrium quantum theoryQuantum dynamicsLiouville operators82C10; 47N50FOS: Physical sciencesFeshbach mapQuantum phasesSpectral deformation theory01 natural sciencesOpen quantum systemQuantum mechanics0103 physical sciencesQuantum operationStatistical physics0101 mathematicsQuantum statistical mechanicsMathematical PhysicsMathematicsQuantum discord82C10010102 general mathematicsMathematical Physics (math-ph)Quantum dynamical systemsQuantum process47N50010307 mathematical physicsQuantum dissipationAnalysis
researchProduct

Spatial quantum noise interferometry in expanding ultracold atom clouds

2005

It is ten years since the exotic form of matter known as a Bose–Einstein condensate was first created. It was the birth of ultra-low-temperature physics, and practitioners gathered last month in Banff, Canada, to celebrate and discuss the latest news, as Karen Fox reports. And this week a new development that could have a major impact in the field is announced. In the 1950s, Hanbury Brown and Twiss showed that it is possible to measure angular sizes of astronomical radio sources from correlations of signal intensities in independent detectors. ‘HBT interferometry’ later became a key technique in quantum optics, and now it has been harnessed to identify a quantum phase of ultracold bosonic a…

Nuclear TheoryFOS: Physical sciencesQuantum phases01 natural sciences010305 fluids & plasmaslaw.invention010309 opticslawUltracold atomQuantum mechanics0103 physical sciencesPhysics::Atomic PhysicsNuclear Experiment010306 general physicsQuantum statistical mechanicsQuantumCondensed Matter::Quantum GasesQuantum opticsPhysicsOptical latticeMultidisciplinaryMott insulatorQuantum noiseShot noiseCondensed Matter - Other Condensed Matter[PHYS.COND.CM-GEN]Physics [physics]/Condensed Matter [cond-mat]/Other [cond-mat.other]Atom opticsAtomic physicsBose–Einstein condensateOther Condensed Matter (cond-mat.other)Nature
researchProduct

Mitomycin 'C' and vinorelbine as second line chemotherapy for metastatic breast carcinoma

1994

Aims and background Patients with metastatic breast carcinoma resistant to first line chemotherapy may require further treatment. Results o second line chemotherapy are still largerly unsatisfactory. For this reason a phase II study on the combination of mitomycin C and vinorelbine was carried out. Methods Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i.v. on day 1, and vinorelbine 25 mg/m2 i.v. on days 1 and 8. This cycle was repeated every 28 days. Responses were evaluated according to the WHO criteria. Results A major objective response was recorded in 16 cases (40%; 95% confidence limits 32%-48%), with 2 pat…

OncologyAdultCancer Researchmedicine.medical_specialtyAnthracyclineMitomycinPhases of clinical researchBreast NeoplasmsVinorelbineVinblastineGastroenterologyDrug Administration Schedule030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedLeukopeniabusiness.industryMitomycin CCarcinomaVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemedicine.symptombusinessProgressive diseasemedicine.drug
researchProduct

Treatment of metastatic breast cancer with vinorelbine and docetaxel.

2006

Objective: A phase II study was performed to evaluate efficacy and safety of the combination vinorelbine and docetaxel in patients with metastatic breast cancer previously treated with anthracycline-based regimens. Overall 41 patients were included in the study. Methods: Treatment consisted of vinorelbine 25 mg/m 2 and docetaxel 75 mg/m 2 , both administered on day 1 every 3 weeks for a maximum of 9 cycles. Most patients (92%) were postmenopausal with a median age of 57 years, and median ECOG performance of 1. Sites of disease were viscera in 42% of patients, bones in 30%, soft-tissues in 32%. Sixty-five percent of patients had >2 metastatic sites. Previous treatments included neo-adjuvant …

OncologyAdultCancer Researchmedicine.medical_specialtyDocetaxel; Metastatic breast cancer; VinorelbineAnthracyclinemedicine.medical_treatmentPhases of clinical researchBreast NeoplasmsDocetaxelNeutropeniaVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMucositisMedicineHumansInfusions IntravenousChemotherapybusiness.industryVinorelbineMiddle Agedmedicine.diseaseMetastatic breast cancerMetastatic breast cancerSurvival AnalysisTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessmedicine.drugAmerican journal of clinical oncology
researchProduct

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: A phase II study of the Southern Italy Oncology G…

1998

Lonidamine (LND) is a unique antineoplastic drug derived from indazole-3-carboxylic acid which inhibits oxygen consumption and aerobic glycolysis, interfering with energy metabolism of neoplastic cells. LND has been experimentally shown to potentiate the cytotoxic effects of epirubicin (EPI) in human breast cancer cell lines, cisplatin activity in both platinum-sensitive and -resistant human ovarian carcinoma cell lines, and EPI antineoplastic activity in some recent phase III trials carried out in advanced breast cancer. A multicenter phase II trial was carried out with the combination of cisplatin 60 mg/m2, EPI 100 mg/m2 and LND 450 mg/day p.o. in three refracted doses/day starting 2 days…

OncologyAdultCancer Researchmedicine.medical_specialtyIndazolesmedicine.medical_treatmentPhases of clinical researchAdministration OralBreast NeoplasmsDrug Administration Schedulechemistry.chemical_compoundBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinPharmacologyChemotherapybusiness.industryLonidamineCancerMiddle Agedmedicine.diseaseMetastatic breast cancerOncologychemistryFemaleCisplatinbusinessProgressive diseaseEpirubicinmedicine.drug
researchProduct

“Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study”

2004

<i>Objectives:</i> We conducted a multicenter phase II study to evaluate the clinical efficacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine as first-line treatment of metastatic breast cancer patients. <i>Methods:</i> We enrolled 58 patients, 52% of whom had received a previous anthracycline-containing chemotherapy. The treatment schedule was: docetaxel 35 mg/m<sup>2</sup> and gemcitabine 800 mg/m<sup>2</sup> i.v. on days 1, 8, 15 every 28 days. <i>Results:</i> All patients were assessable for toxicity and 56 for efficacy. Overall response rate was 64.3% with 16.1% of complete responses and 48…

OncologyAdultCancer Researchmedicine.medical_specialtyMaximum Tolerated Dosemedicine.drug_classPhases of clinical researchBreast NeoplasmsDocetaxelAntimetaboliteDeoxycytidineMetastasisBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedNeoplasm Stagingbusiness.industryCarcinoma Ductal BreastGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgerySurvival RateCarcinoma LobularTreatment OutcomeOncologyDocetaxelCarcinoma MedullaryToxicityFemaleTaxoidsbusinessmedicine.drug
researchProduct

Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.

2002

<i>Objective:</i> We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and docetaxel in chemotherapy-naive women with advanced breast cancer. <i>Methods:</i> A total of 73 patients with PS (ECOG) 0–2, aged <70 years and adequate bone marrow, renal, liver and cardiac functions were included in the study (13 stage III B and 60 stage IV). The schedule of administration was doxorubicin 50 mg/m<sup>2</sup> by intravenous (i.v.) 30 min injection on day 1 followed the day after by docetaxel 75 mg/m<sup>2</sup>, by i.v. 60 min infusion. Cycles were repeate…

OncologyAdultCancer Researchmedicine.medical_specialtyPaclitaxelPhases of clinical researchBreast NeoplasmsDocetaxelNeutropeniaBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedNeoplasm StagingCumulative dosebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSurvival RateRegimenTreatment OutcomeOncologyDocetaxelTolerabilityDoxorubicinFemaleTaxoidsbusinessFebrile neutropeniamedicine.drugOncology
researchProduct

TRIPLET SCHEDULE OF WEEKLY 5-FLUOROURACIL AND ALTERNATING IRINOTECAN OR OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A DOSE-FINDING AND PHASE II STUDY.

2010

A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsMaximum Tolerated DoseOrganoplatinum CompoundsSettore MED/06 - Oncologia Medica5-FluorouracilPhases of clinical researchIrinotecanGastroenterologyInternal medicineCPT-11Antineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdvanced colorectal cancerAgedDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseOxaliplatinIrinotecanOxaliplatinSurvival RateRegimenTreatment OutcomeOncologyTolerabilityFluorouracilLymphatic MetastasisToxicityl-OHPCamptothecinFemaleFluorouracilbusinessColorectal NeoplasmsFebrile neutropeniamedicine.drug
researchProduct

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal ca…

2006

Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU). We carried out this phase II study to assess the activity and toxicity of a biweekly regimen including OXA plus IRI on day 1, and levo-folinic acid (LFA) plus 5FU on day 2 (OXIRIFAFU) in pretreated patients with metastatic colorectal cancer. Forty-one patients, all previously treated with adjuvant and/or palliative 5FU-based chemotherapy (16 of them already exposed to IRI, OXA or both), were enrolled into this trial. On the basis of sensitivity to previous treatme…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerLeucovorinPhases of clinical researchIrinotecanDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedPharmacologybusiness.industryMiddle Agedmedicine.diseasedigestive system diseasesSurgeryOxaliplatinIrinotecanOxaliplatinOncologyFluorouracilToxicityInjections IntravenousDisease ProgressionCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugAnti-cancer drugs
researchProduct